# US 2026/0060939 A1 · Treatment for management and prevention of eyelid conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060939 A1
- Document ID: US20260060939A1
- Status: Published application
- Kind: A1
- Application number: 19/263,917
- Filed: 2025-07-09
- Published: 2026-03-05
- Earliest claimed: 2024-08-28
- Inventors: John Olkowski; Erika Olkowski
- Web page: https://patentgrep.com/patent/US20260060939A1

## CPC

- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 36/3482: {Cannabis}
- A61K 36/534: Mentha (mint)
- A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A61K 36/752: Citrus, e.g. lime, orange or lemon
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Blepharitis, an infection and inflammation of the edge of the eyelids, and meibomian gland dysfunction (MGD), blockage of tiny oil glands at the eye lid margin, are quite common, usually under diagnosed and underappreciated diseases. There are number of causes for blepharitis, including bacterial components such as Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes and Corynebacteria sp., seborrhea or microscopic mites (Demodex). More than 50% of patients seeking ophthalmologic consultations have symptoms and signs indicating one of these entities. Another large number of patients remain undiagnosed or in early stages of disease that could be easily treated thus preventing long-term pain and suffering. MGD is in fact the leading cause of dry eye disease, a potentially preventable malady.

## Claims

### Claim 1

A composition for treating eyelid conditions, comprising:
carvacrol; and
a therapeutic oil selected from the group consisting of an essential oil, a CBD oil, a cannabis oil, and other cannabis-derived oils,
wherein the carvacrol and the therapeutic oil are combined to form a mixture.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the carvacrol is sonicated in the therapeutic oil.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition is in a form selected from the group consisting of a cream, a serum, a gel, an ointment, and a lotion.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition is formulated for topical application to an eyelid.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition is effective for treating blepharitis.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition is effective for treating at least one of: chalazion, stye, dry eye syndrome, eyelid dermatitis, and meibomian gland dysfunction.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the carvacrol is present in a concentration range of 0.1% to 10% by weight of the composition.

### Claim 8

A method of treating an eyelid condition, comprising:
applying a composition to an eyelid of a subject, the composition comprising carvacrol and a therapeutic oil selected from the group consisting of an essential oil, a CBD oil, a cannabis oil, and other cannabis-derived oils,
wherein the carvacrol and the therapeutic oil are combined to form a mixture.

### Claim 9 (depends on 8)

The method of claim 8, wherein the eyelid condition is blepharitis.

### Claim 10 (depends on 9)

The method of claim 9, wherein the eyelid condition further includes at least one of: chalazion, stye, dry eye syndrome, eyelid dermatitis, and meibomian gland dysfunction.

### Claim 11 (depends on 8)

The method of claim 8, wherein the composition is applied topically to the eyelid.

### Claim 12 (depends on 11)

The method of claim 11, wherein the composition is in a form selected from the group consisting of a cream, a serum, a gel, an ointment, and a lotion.

### Claim 13 (depends on 8)

The method of claim 8, wherein the carvacrol is present in a concentration range of 0.1% to 10% by weight of the composition.

### Claim 14 (depends on 13)

The method of claim 13, wherein the therapeutic oil is present in a concentration range of 0.1% to 100% by weight of the composition.

### Claim 15

A kit for treating an eyelid condition, comprising:
a composition comprising carvacrol and a therapeutic oil selected from the group consisting of an essential oil, a CBD oil, a cannabis oil, and other cannabis-derived oils, wherein the carvacrol and the therapeutic oil are combined to form a mixture; and
instructions for use.

### Claim 16 (depends on 15)

The kit of claim 15, wherein the composition is in a form selected from the group consisting of a cream, a serum, a gel, an ointment, and a lotion.

### Claim 17 (depends on 15)

The kit of claim 15, wherein the composition is effective for treating blepharitis.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the composition is effective for treating at least one of: chalazion, stye, dry eye syndrome, eyelid dermatitis, and meibomian gland dysfunction.

### Claim 19 (depends on 15)

The kit of claim 15, wherein the carvacrol is present in a concentration range of 0.1% to 10% by weight of the composition.

### Claim 20 (depends on 19)

The kit of claim 19, wherein the therapeutic oil is present in a concentration range of 0.1% to 100% by weight of the composition.
